Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.parkreldis.2011.09.023PMID 22000279
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study

  2010cited by this paper
• Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

  2008cited by this paper
• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  2008cited by this paper
• A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

  2008cited by this paper
• Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions

  2008cited by this paper
• Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease

  2005cited by this paper
• Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors

  2003cited by this paper
• Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2A Receptor Antagonist

  2000cited by this paper
• Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

  2000cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

  1990cited by this paper

• Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study.

  2026cites this paper
• Modulation of hierarchical motor sequence learning by alpha-synuclein and the adenosine A2A receptor.

  2026cites this paper
• Concordance between EMA Good Clinical Practice inspections and medical literature concerning drugs that have not received marketing authorization in the European Union: a meta-research survey

  2025cites this paper
• Treatment strategies for motor fluctuations in Parkinson’s disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America

  2025cites this paper
• Concordance between European medicine agency good clinical practice inspections and medical literature: a meta-research survey

  2025cites this paper
• Microbiota–gut–brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets

  2025cites this paper
• Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies

  2025cites this paper
• Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease

  2025cites this paper
• Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review

  2025cites this paper
• Safety Profile of Istradefylline in Parkinson’s Disease: A Meta-Analysis of Randomized Controlled Trials and Disproportionality Analysis Using FAERS

  2025cites this paper
• CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial

  2024cites this paper
• Prescription trends in Japanese advanced Parkinson’s disease patients with non-motor symptoms: J-FIRST

  2024cites this paper
• Factors associated with a placebo effect in Parkinson’s disease in clinical trials: a meta-analysis

  2024cites this paper
• The role of istradefylline in the Parkinson’s disease armamentarium

  2023cites this paper
• Anti-parkinsonian activity of the adenosine A2A receptor antagonist/inverse agonist KW-6356 as monotherapy in MPTP-treated common marmosets.

  2023cites this paper
• Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis

  2023cites this paper
• Molecular and Structural Insight into Adenosine A2A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach

  2023cites this paper
• How and why the adenosine A2A receptor became a target for Parkinson's disease therapy.

  2023cites this paper
• Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios

  2022cites this paper
• Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease

  2022cites this paper
• nnEfficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.

  2022cites this paper
• Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease.

  2022cites this paper
• Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?

  2022cites this paper
• Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios

  2022cites this paper
• The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease

  2022cites this paper
• A Review of Randomized Phase III Pharmacological Clinical Trials for Motor Symptoms in Parkinson’s Disease Patients and Quality of Evidence Recommendations

  2021cites this paper
• Clinical Trials In Parkinson's Disease

  2021influential citation
• Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease

  2021cites this paper
• Stereotypy and spontaneous alternation in deer mice and its response to anti‐adenosinergic intervention

  2021cites this paper
• Adenosin A 2A Rezeptorantagonisten als Therapieoption beim idiopathischen Parkinson-Syndrom?

  2021cites this paper
• Istradefylline Versus Opicapone for “Off” Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis

  2021cites this paper
• Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease

  2021cites this paper
• Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists

  2021cites this paper
• Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials

  2021cites this paper
• Clinical Trials for Motor Complications in Parkinson’s Disease

  2021cites this paper
• Immunomodulatory Effects of Dopamine in Inflammatory Diseases

  2021cites this paper
• A Review of Randomized Pharmacological for in Parkinson’s Patients and Recommendations

  2020cites this paper
• Istradefylline: a novel drug for ‘off’ episodes in Parkinson’s disease

  2020cites this paper
• The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant.

  2020cites this paper
• Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review

  2020cites this paper
• Overview of therapeutic drugs and methods for the treatment of Parkinson's disease.

  2020cites this paper
• Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update

  2020cites this paper
• Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson’s Disease

  2020cites this paper
• Striatopallidal adenosine A2A receptors in the nucleus accumbens confer motivational control of goal-directed behavior.

  2020cites this paper
• Clinical Trials for in Parkinson’s

  2020cites this paper
• Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders.

  2019cites this paper
• Istradefylline for Treating Parkinson’s Disease

  2019cites this paper
• The next chapter in symptomatic Parkinson disease treatments.

  2019cites this paper
• Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease

  2019cites this paper
• From medications to surgery: advances in the treatment of motor complications in Parkinson’s disease

  2019cites this paper
• Complications of levodopa therapy in Parkinson’s disease

  2019cites this paper
• Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson's disease using 11C‐preladenant PET

  2018cites this paper
• Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients

  2018cites this paper
• Clinical Efficacy of Istradefylline for Depression in Parkinson’s Disease

  2018cites this paper
• IDENTIFICATION OF POSSIBLE MOLECULAR TARGETS OF POTENTIAL ANTI-PARKINSON DRUGS BY PREDICTING THEIR BINDING AFFINITIES USING MOLECULAR DOCKING TECHNIQUE

  2018cites this paper
• NOVEL DEVELOPMENTS IN IMMUNE CHECKPOINT THERAPY

  2018cites this paper
• International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

  2018cites this paper
• Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey

  2018cites this paper
• Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?

  2018cites this paper
• The effect of istradefylline for Parkinson’s disease: A meta-analysis

  2017cites this paper
• Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease

  2017cites this paper
• Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease

  2017cites this paper
• Recent advances in treating Parkinson’s disease

  2017cites this paper
• The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease

  2017cites this paper
• A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L‐DOPA‐induced dyskinesia in Parkinson's disease

  2017cites this paper
• Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects

  2017cites this paper
• Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease

  2017influential citation
• Differences between Istradefylline Responders and Non-Responders in Parkinson’s Disease

  2017cites this paper
• How does adenosine control neuronal dysfunction and neurodegeneration?

  2016cites this paper
• New and emerging medical therapies in Parkinson’s disease

  2016cites this paper
• Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease.

  2016cites this paper
• Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson's Disease.

  2016cites this paper
• Nondopaminergic treatments for Parkinson's disease: current and future prospects.

  2016cites this paper
• An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.

  2016influential citation
• Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective.

  2016cites this paper
• History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents

  2015cites this paper
• The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease

  2015influential citation
• A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease

  2015cites this paper
• Management of Parkinson׳s disease: Current and future pharmacotherapy.

  2015cites this paper
• Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials

  2015cites this paper
• Chapter 7 Interventions for fatigue in Parkinson ’ s disease : a Cochrane Review

  2015cites this paper
• Molecular imaging of levodopa-induced dyskinesias

  2015cites this paper
• Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease

  2015cites this paper
• The safety of istradefylline for the treatment of Parkinson’s disease

  2015cites this paper
• Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.

  2015cites this paper
• 2-Aminopyrimidines as dual adenosine A1/A2A antagonists.

  2015cites this paper
• Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease

  2015cites this paper
• Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson’s Disease

  2015cites this paper
• The Story of Istradefylline—The First Approved A2A Antagonist for the Treatment of Parkinson’s Disease

  2015cites this paper
• Synthesis of a series of novel 2- aminopyrimidine derivatives and their biological evaluation as adenosine receptor antagonists

  2015cites this paper
• Interventions for fatigue in Parkinson's disease.

  2015cites this paper
• Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease

  2014cites this paper
• Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis

  2014cites this paper
• Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions

  2014cites this paper
• Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.

  2014cites this paper
• Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

  2014cites this paper
• Adenosine receptors and dyskinesia in pathophysiology.

  2014cites this paper
• Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

  2014cites this paper
• Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b.

  2014cites this paper
• Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials

  2014cites this paper